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as PTSD was not discovered, but rather was
created, or "glued together", "by the practices,
technologies and narratives with which it is
diagnosed, studied, treated and represented . . ."
(p. 5), a claim he convincingly supports in this
thought-provoking, though uneven book.
Significantly, Young does not deny the
"reality" ofpost-traumatic suffering; rather his
goal is to lay bare the construction ofthat
reality through the discourses and practices of
contemporary psychiatry.
Composed ofthree somewhat disjointed
sections, which Young fails to integrate
adequately, the book documents three ways in
which PTSD has been constructed: by the
(inaccurate) assertion of a continuous history;
in the "political" and diagnostic struggles of
post-war American psychiatry; and, most
interestingly, through current psychiatric
practice and psychiatric science.
The historical section, the weakest part of
this book, analyses theories of trauma and
memory from John Eric Erichsen's "railway
spine" diagnosis ofthe 1860s through the so-
called war neuroses ofthe First World War.
The highlight ofthe section is Young's
discussion ofW H R Rivers and the treatment
ofshell-shock, in which he undermines the
common view that celebrates the English
neurologist as a "progressive" precursor to
contemporary thinking on PTSD. However,
other than refuting the linear histories written
by psychiatric insiders, Young adds little new
material to a subject that will be familiar to
most specialized readers and was thoroughly
covered over two decades ago by the Swiss
medical historian, Esther Fischer-Homberger
(who, strikingly, does not appear in his
bibliography). Furthermore, his historical
section pays regrettably little attention to
national context and occasionally makes false
claims, such as the assertion that the inter-war
period saw little medical interest in psychic
trauma, when, in fact, the so-called "accident
neuroses" inspired vigorous debate among
Continental doctors throughout the 1920s.
Skipping ahead thirty years, Young moves
onto firmer ground in the second section,
which is devoted to the creation ofthe PTSD
diagnosis in the post-war American psychiatric
profession. Recounting the victory ofthe neo-
Kraepelinians in their struggle against
psychodynamic psychiatry, he assesses the
impact ofpositivistic psychiatric classification
on theories oftraumatic memory. Diagnostic
technologies, Young suggestively argues, rather
than better classifying "real" conditions,
actually help form the maladies they purport to
identify and describe.
The third section contains a fascinating-
and often disturbing-glimpse into daily life at
a centre for the treatment oftraumatized
Vietnam war veterans. By recounting case
histories and revealing the dynamics ofgroup
therapy sessions, Young shows how patients'
experiences are moulded into narratives that fit
the accepted symptomological and
chronological criteria for PTSD, and how the
centre's "ideology" functions to produce the
desired psychiatric knowledge. His
ethnographic method and the absorbing case
histories make this the most compelling and
persuasive section ofthe book.
While it is now standard for historians to
show how psychiatric knowledge has been
constructed by the discourses, professional
contexts and social practices ofpast periods, it
is a far more serious challenge to unveil these
same processes at work in contemporary
settings. That is the achievement ofthis
flawed, but richly provocative book.
Paul Lerner, Wellcome Institute
Louis Galambos with Jane Eliot Seweli,
Networks ofinnovation: vaccine development
atMerck, Sharp & Dohme, andMulford,
1895-1995, Cambridge University Press, 1995,
pp. xii, 273, illus., £35.00 (0-521-56308-9).
People will ask: is this a commissioned
company history? Yes and no. The authors, an
American business historian and a British
medical historian, say they first wrote an
"internal" history ofvaccine and anti-toxin
development in these companies, then
expanded their study with wider research and
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contextualization to produce a scholarly
volume. Company personnel are praised for
co-operation without any attempt at control
over the authors' interpretations. The title,
impeccably in tune with recent trends in the
history ofscience, medicine and technology,
promises a bold contribution to the
historiography ofan undoubtedly neglected
area. How well does the text measure up to this
promise?
The book succeeds in conveying broad
sweeps ofinnovation and stagnation, linked to
changes in science, together with political and
economic shifts that affected markets for
"biologicals", with vaccines as the epitome of
preventive medicine. Galambos and Sewell
locate the success ofMulford's company in
two networks which grew towards the end of
the nineteenth century: public health in big
American cities, and biological therapies based
on ideas imported from Europe. From business
history, the notion oflong cycles has been
adapted to give "long cycles ofinnovation" in
research, development and marketing of
biologicals, which yielded diminishing returns.
Why was this? Did scientific paradigms "wear
out" as they were superseded by further
innovations? The authors blame lack of
vigorous leadership forMulford's stagnation,
leading to takeover by Sharp & Dohme in
1929. However, the new bosses seem also to
have lacked innovative vigour in the vaccine
field, being more attracted by the sulfa drugs
and antibiotics.
Military research features prominently
among the networks offering a way forward in
the 1950s, together with virology's expansion
through electron microscopy and tissue culture.
Following merger with Merck (1954), thejoint
company's vaccine production was transformed
from 1957 by Maurice Hilleman, whose
experience in paediatric and military
respiratory virus research and vaccine
development nurtured a new cycle of
innovation. The central chapters describe an
exciting period ofproduct development under
Hilleman, crowned with ajoint measles,
mumps and rubella vaccine licensed in 1971.
Fluctuating fortunes in the 1970s are vividly
illustrated by the swine influenza fiasco, "a
drama in medical, public health and political
history" (p. 138), followed by an internal study
querying the future ofthe company's
involvement in vaccines. Recovery came
through innovation in vaccines against
bacterial diseases such as meningitis; plus two
lines ofhepatitis B vaccine, the second of
which led Merck into recombinant DNA
biotechnology. The story ends in the 1990s
with a briefcritique ofClinton's policy on
immunization, depicted as counter to the
successful mixed economy ofvaccine
production in the U.S. A difference ofopinion
between the two authors on mixed
public/private systems is attributed to their
nationalities (p. 229, n. 53) but might also be
explained in part by their different disciplines,
with the (American) business historian perhaps
more partial to a company's-eye-view ofthe
public sector as interfering and cumbersome.
There are particular quibbles, for example
trials on institutionalized children and extra-
U.S. populations need to be explained, not
glossed over; and Merck's difficulties in
providing cheaper vaccines for developing
countries merit fuller exploration. A more
general problem is over-reliance on personality
as explanation, which might have been
modified with more attention to recent
historical studies. Networks are often
mentioned but insufficiently explicated: more
is needed especially on the separate but
connected world ofgovernment-funded
vaccine research. But this is after all
principally an account ofone firm's work, in
itself a highly complex story told here with
admirable poise.
Jennifer Stanton,
London School ofHygiene and Tropical
Medicine
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